

Dkt. 1567/73236/JPW/AG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Abraham Loyter et al.  
 Serial No.: 10/511,990  
 Filed : October 21, 2004  
 For : ANTI-NLS SCFV AND PEPTIDES AND USES THEREOF  
 IN NUCLEAR IMPORT INHIBITION

1185 Avenue of the Americas  
 New York, New York 10036  
 July 28, 2005

Mail Stop: Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following disclosures (**Exhibits 1-50**) which are listed on Form PTO-1449 (**Exhibit A**).

1. WO 99/28338, issued June 10, 1999 (**Exhibit 1**);
2. WO 00/49038, issued August 24, 2000 (**Exhibit 2**);
3. Adam, S.A. et al., (1992) Nuclear Protein Import Using Digitonin-Permeabilized Cells, *Methods in Enzymology*, 219, pp:97-110 (**Exhibit 3**);

Applicants: Abraham Loyter et al.  
Serial No.: 10/511,990  
Filed : October 21, 2004  
Page 2

4. Agostini, I. et al., (2000) Heat-Shock Protein 70 Can Replace Viral Protein R of HIV-1 during Nuclear Import of the Viral Preintegration Complex, *Experimental Cell Research*, 259, pp:398-403 (Exhibit 4);
5. Baeuerle, P.A., and D. Baltimore, (1988) I $\kappa$ B: A Specific Inhibitor of the NF- $\kappa$ B Transcription Factor, *Science*, 242, pp:540-546 (Exhibit 5);
6. Bailey, T.L. and C. Elkan, (1994) Fitting a Mixture Model by Expectation Maximization to Discover Motifs in Biopolymers, *Proceedings of the Second International Conference on Intelligent Systems for Molecular Biology*, pp:28-36 (Exhibit 6);
7. Baldrich-Rubio, E. et al., (2001) A Complex Human Immunodeficiency Virus Type 1 A/G/J Recombinant Virus Isolated from a Seronegative Patient with AIDS from Benin, West Africa, *Journal of General Virology*, 82(Pt.5), pp:1095-1106 (Exhibit 7);
8. Bouyac-Bertoia, M. et al., (2001) HIV-1 Infection Requires a Function Integrase NLS, *Molecular Cell*, 7(5), pp:1025-1035 (Exhibit 8);
9. Broder, Y.C. et al., (1997) Translocation of NLS-BSA Conjugates into Nuclei of Permeabilized Mammalian Cells Can Be Supported by Protoplast Extract: An Experimental

Applicants: Abraham Loyter et al.  
Serial No.: 10/511,990  
Filed : October 21, 2004  
Page 3

System for Studying Plant Cytosolic Factors Involved in  
Nuclear Import, *FEBS Letters*, 412, pp:535-539 (Exhibit 9);

10. Bukrinsky, M. et al., (1992) Active Nuclear Import of Human Immunodeficiency Virus Type 1 Preintegration Complexes, *Proc. Natl. Acad. Sci. USA*, 89(14), pp: 6580-6584 (Exhibit 10);
11. Bukrinsky, M. et al., (1993a) A Nuclear Localization Signal Within HIV-1 Matrix Protein that Governs Infection of Non-Dividing Cells, *Nature*, 365, pp:666-669 (Exhibit 11);
12. Burinsky, M. et al., (1993b) Association of Integrase, Matrix, and Reverse Transcriptase Antigens of Human Immunodeficiency Virus Type 1 with Viral Nucleic Acids Following Acute Infection, *Proc. Natl. Acad. Sci. USA*, 90, pp:6125-6129 (Exhibit 12);
13. Choudhury, I. et al., (1998) Inhibition of HIV-1 Replication by a Tat RNA-Binding Domain Peptide Analog, *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 17(2), pp:104-111 (Exhibit 13);
14. Cullen B.R., (1993) Does HIV-1 Tat Induce a Change in Viral Initiation Rights?, *Cell*, 73(3), pp.417-420 (Exhibit 14);
15. Cullen, B.R., (1995) Regulation of HIV Gene Expression, *AIDS*, 9(suppl. A) pp:S19-S32 (Exhibit 15);

Applicants: Abraham Loyter et al.  
Serial No.: 10/511,990  
Filed : October 21, 2004  
Page 4

16. Cullen, B.R., (1998) HIV-1 Auxiliary Proteins: Making Connections in a Dying Cell, *Cell*, 93, pp:685-692 (Exhibit 16);
17. de Noronha, C.M. et al., (2001) Dynamic Disruptions in Nuclear Envelope Architecture and Integrity Induced by HIV-1 Vpr, *Science*, 294, pp: 1105-1108 (Exhibit 17);
18. Depienne, C. et al., (2000) Cellular Distribution and Karyophilic Properties of Matrix, Integrase, and Vpr Proteins from the Human and Simian Immunodeficiency Viruses, *Experimental Cell Research*, 260, pp:387-395 (Exhibit 18);
19. Dubrovsky, L. et al., (1995) Nuclear Localization Signal of HIV-1 as a Novel Target for Therapeutic Intervention, *Molecular Medicine*, 1(2), pp:217-230 (Exhibit 19);
20. F.C.L. Almeida and S.J. Opella, (1997) fd Coat Protein Structure in Membrane Environments: Structural Dynamics of the Loop Between the Hydrophobic Trans-Membrane Helix and the Amphipathic In-Plane Helix, *J. Mol. Biol.*, 270, pp: 481-495 (Exhibit 20);
21. Friedler, A. et al., (1998) Backbone Cyclic Peptide, Which Mimics the Nuclear Localization Signal of Human Immunodeficiency Virus Type 1 Matrix Protein, Inhibits

Applicants: Abraham Loyter et al.  
Serial No.: 10/511,990  
Filed : October 21, 2004  
Page 5

Nuclear Import and Virus Production in Nondividing Cells,  
*Biochemistry*, 37, pp:5616-5622 (Exhibit 21);

22. Friedler, A. et al., (1999) Identification of a Nuclear Transport Inhibitory Signal (NTIS) in the Basic Domain of HIV-1 Vif Protein, *J. Mol. Biol.*, 289, pp:431-437 (Exhibit 22);
23. Gallay, P. et al., (1997) HIV-1 Infection of Nondividing Cells Through the Recognition of Integrase by the Importin/Karyopherin Pathway, *Proc. Natl. Acad. Sci. USA*, 94, pp:9825-9830 (Exhibit 23);
24. Goldfarb, D. and N. Michaud, (1991) Pathways for the Nuclear Transport of Proteins and RNAs, *Trends in Cell Biology*, 1, pp:20-24 (Exhibit 24);
25. Goldfarb, D.S. et al., (1986) Synthetic Peptides as Nuclear Localization Signals, *Nature*, 322, pp:641-644 (Exhibit 25);
26. Görlich, D., and I.W. Mattaj, (1996) Nucleocytoplasmic Transport, *Science*, 271, pp:1513-1518 (Exhibit 26);
27. Graessmann, M., and A. Graessmann, (1983) Microinjection of Tissue Culture Cells, *Methods in Enzymology*, 101, pp:482-493 (Exhibit 27);

Applicants: Abraham Loyter et al.  
Serial No.: 10/511,990  
Filed : October 21, 2004  
Page 6

28. Haffar, O.K., et al., (2000) Two Nuclear Localization Signals in the HIV-1 Matrix Protein Regulate Nuclear Import of the HIV-1 Pre-integration Complex, *J. Mol. Biol.*, 299, pp:359-368 (Exhibit 28);
29. Harrison, J.L. et al., (1996) Screening of Phage Antibody Libraries, *Methods in Enzymology*, 267, pp:83-109 (Exhibit 29);
30. Heinzinger, N.K. et al., (1994) The Vpr Protein of Human Immunodeficiency Virus Type 1 Influences Nuclear Localization of Viral Nucleic Acids in Nondividing Host Cells, *Proc. Natl. Acad. Sci. USA*, 91, pp:7311-7315 (Exhibit 30);
31. Jenkins, Y. et al., (1998) Characterization of HIV-1 Vpr Nuclear Import: Analysis of Signals and Pathways, *J. Cell Biol.*, 143(4), pp:875-885 (Exhibit 31);
32. Johnsson, K. and L. Ge, (1999) Phage Display of Combinatorial Peptide and Protein Libraries and Their Applications in Biology and Chemistry, *Curr. Top. Microbiol. Immunol.*, 243, pp:87-105 (Exhibit 32);
33. Karni, O. et al., (1998) A peptide Derived from the N-terminal Region of HIV-1 Vpr Promotes Nuclear Import on Permeabilized Cells: Elucidation of the NLS Region of the Vpr, *FEBS*, 429, pp:7151-7158 (Exhibit 33);

Applicants: Abraham Loyter et al.  
Serial No.: 10/511,990  
Filed : October 21, 2004  
Page 7

34. Koostra, N.A., and H. Schuitemaker, (1999) Phenotype of HIV-1 Lacking a Functional Nuclear Localizaion Signal in Matrix Protein of GAG and Vpr is Comparable to Wild-Type in HIV-1 Primary Macrophages, *Virology*, 253(2), pp:170-180 (Exhibit 34);
35. Laemmli, U.K., (1970) Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4, *Nature*, 227, pp:680-685 (Exhibit 35);
36. Lewis, P. et al., (1992) Human Immunodeficiency Virus Infection of Cells Arrested in the Cell Cycle, *The EMBO Journal*, 11(8), pp:3053-3058 (Exhibit 36);
37. Lewis, P.F. and M. Emerman, (1994) Passage through Mitosis Is Required for Oncoretroviruses but Not for the Human Immunodeficiency Virus, *Journal of Virology*, 68(1), pp:510-516 (Exhibit 37);
38. Luo, Z. et al., (1998) Structural Studies of Synthetic Peptide Fragments Derived from the HIV-1 Vpr Protein, *Biochemical and Biophysical Research Communications*, 244, pp:732-736 (Exhibit 38);
39. Nissam, A. et al., (1994) Antibody Fragments from a 'Single Pot' Phage Display Library as Immunochemical Reagents, *The EMBO Journal*, 13(3), pp:692-698 (Exhibit 39);

Applicants: Abraham Loyter et al.  
Serial No.: 10/511,990  
Filed : October 21, 2004  
Page 8

40. Petit, C. et al., (2000) The Karyophilic Properties of Human Immunodeficiency Virus Type 1 Integrase Are Not Required for Nuclear Import of Proviral DNA, *Journal of Virology*, 74(15), pp:7119-7126 (Exhibit 40);
41. Piller, S. et al., (1996) Vpr Protein of Human Immunodeficiency Virus Type 1 Forms Cation-Selective Channels in Planar Lipid Bilayers, *Proc. Natl. Acad. Sci. USA*, 93, pp:111-115 (Exhibit 41);
42. Pollard, V.W. and M. H. Malim, (1998) The HIV-1 Rev Protein, *Annu. Rev. Microbiol.*, 52, pp:491-532 (Exhibit 42);
43. Popov, S. et al., (1998) Viral Protein R Regulates Nuclear Import of the HIV-1 Pre-Integration Complex, *The EMBO Journal*, 17(4), pp:909-917 (Exhibit 43);
44. Rasched, I. and E. Oberer, (1986) Ff Coliphages: Structural and Function Relationships, *Microbiological Reviews*, 50(4), pp:401-427 (Exhibit 44);
45. Schneider, J. et al., (1988) A Mutant SV40 Large T Antigen Interferes with Nuclear Localization of a Heterologous Protein, *Cell*, 54, pp:117-125 (Exhibit 45);
46. Simm, L.G. et al., (1993) Human Immunodeficiency Virus Type 1 DNA Synthesis, Integration, and Efficient Viral



Applicants: Abraham Loyter et al.  
Serial No.: 10/511,990  
Filed : October 21, 2004  
Page 9

Replication in Growth-Arrested T Cells, *Journal of Virology*, 67(7), pp:3969-3977 (Exhibit 46);


47. Thompson, J.D. et al., (1994) Clustal W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice, *Nucleic Acids Research*, 22(2), pp:4673-4680 (Exhibit 47);
48. Truant, R. and B.R. Cullen, (1999) The Arginine-Rich Domains Present In Human Immunodeficiency Virus Type 1 Tat and Rev Function as Direct Importin  $\beta$ -Dependent Nuclear Localization Signals, *Molecular and Cellular Biology*, 19(2), pp:1210-1217 (Exhibit 48);
49. Wecker, K. and B.P. Roques, (1999) NMR Structure of the (1-51) N-terminal Domain of the HIV-1 regulatory protein Vpr, *Eur. J. Biochem.*, 266, pp:359-369 (Exhibit 49); and
50. Yuan, X. et al., (1990) Human Immunodeficiency Virus vpr Gene Encodes a Virion-Associated Protein, *AIDS Research and Human Retroviruses*, 6(11), pp:1265-1271 (Exhibit 50).

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Abraham Loyter et al.  
Serial No.: 10/511,990  
Filed : October 21, 2004  
Page 10

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, NY 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: Amendments  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

 7/28/05  
John P. White Date  
Reg. No. 28,678



Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Sheet 2 of 6

Application Number 10/511,990  
Filing Date October 21, 2004  
First Named Inventor LOYTER Abraham  
Art Unit  
Examiner Name  
Attorney Docket Number 73236

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Adam, S.A. et al. (1992) Methods in Enzymology 219, 97-110	
	CB	Agostini, I. et al. (2000) Exp Cell Res 259, 398-403	
	CC	Baeuerle, P.A., and D. Baltimore (1988) Science 242, 540-546	
	CD	Bailey, T.L., and C. Elkan (1994) Fitting a mixture model by expectation maximization to discover motifs. Proceedings of the Second International Conference on Intelligent Systems for Molecular Biology 28-36	
	CE	Baldrich-Rubio, E. et al. (2001) J Gen Virol 82(Pt5), 1095-106	
	CF	Bouyac-Bertoia, M. et al. (2001) Mol Cell 7(5), 1025-35	
	CG	Broder, Y.C. et al. (1997) FEBS Lett. 412, 535-539	
	CH	Bukrinsky, M. et al. (1992) PNAS USA 89(14), 6580-4	
	CI	Bukrinsky, M.I. et al. (1993a) Nature 365, 666-669	
	CJ	Bukrinsky, M. et al. (1993b) PNAS USA 90, 6125-6129	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/511,990
Filing Date	October 21, 2004
First Named Inventor	LOYTER Abraham
Art Unit	
Examiner Name	
Attorney Docket Number	73236

Sheet 3

of 6

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CK	Choudhury, I., J. Wang, et al. (1998) Journal of acquired immuno-deficiency syndromes and human retrovirology 17, 104-111	
	CL	Cullen, B.R. (1993) Cell 73(3), 417-20	
	CM	Cullen, B.R. (1995) Aids 9, S19-32	
	CN	Cullen, B.R. (1998) Cell 93, 685-692	
	CO	de Noronha, C. M. et al. (2001) Science 294(5544): 1105-8	
	CP	Depienne, C. et al. (2000) Exp Cell Res 260, 387-395	
	CQ	Dubrovsky, L. et al. (1995) Molecular Medicine 1(2), 217-230	
	CR	F.C.L. Almeida and S.J. Opella (1997) J. Mol. Biol. 270, 481-495	
	CS	Friedler, A. et al. (1998) Biochemistry 37, 5616-5622	
	CT	Friedler, A. et al. (1999) J Mol Biol 289, 431-437	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/511,990
		Filing Date	October 21, 2004
		First Named Inventor	LOYTER Abraham
		Art Unit	
		Examiner Name	
Sheet 4	of 6	Attorney Docket Number	73236

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CU	Gallay, P. et al. (1997) Proc. Natl. Acad.Sci. USA 94, 9825-9830	
	CV	Goldfarb, D., and N. Michaud (1991) Trends Cell Biol. 1, 20-24	
	CW	Goldfarb, D.S. et al. (1986) Nature 322, 641-644	
	CX	Gorlich, D., and I.W. Mattaj (1996) Science 271, 1513-1518	
	CY	Graessmann, M. and A. Graessmann (1983) Methods Enzymol. 101, 482-92	
	CZ	Haffar, O.K. et al. (2000) J Mol Biol 299, 359-68	
	DA	Harrison, J.L. et al. (1996) Methods in Enzymology 267, 83-109	
	DB	Heinzinger, N.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91, 7311-7315	
	DC	Jenkins, Y. et al. (1998). J Cell Biol 143, 875-885	
	DD	Johnsson, K., and L. Ge (1999) Curr Top Microbiol Immunol 243, 87-105	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/511,990
Filing Date	October 21, 2004
First Named Inventor	LOYTER Abraham
Art Unit	
Examiner Name	
Attorney Docket Number	73236

Sheet 5 of 6

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	DE	Karni, O. et al. (1998) FEBS Let. 429:421-425	
	DF	Koostra, N.A., and H. Schuitemaker (1999) Virology 253(2), 170-180	
	DG	Laemmli, U.K. (1970) Nature 277, 680-685	
	DH	Lewis, P. et al. (1992) EMBO J 11, 3053-3058	
	DI	Lewis, P.F., and Emerman, M. (1994) J. Virol. 68, 510-516	
	DJ	Luo, Z. et al. (1998) BBRC 244, 732-736	
	DK	Nissim, A. et al. (1994) EMBO J 13, 692-698	
	DL	Petit, C. et al. (2000) J Virol 74(15), 7119-26	
	DM	Piller, S.C. et al. (1996) Proc Natl Acad Sci 93, 111-115	
	DN	Pollard, V.W., and M.H. Malim (1998) Annu. Rev. Microbiol. 52, 491-532	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/511,990
Filing Date	October 21, 2004
First Named Inventor	LOYTER Abraham
Art Unit	
Examiner Name	
Attorney Docket Number	73236

Sheet 6

of 6

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	DO	Popov, S. et al. (1998) EMBO J 17, 909-917	
	DP	Rasched, I., and E. Oberer (1986) Microbiol. Rev. 50(4), 401-27	
	DQ	Schneider, J. et al. (1988) Cell 54, 117-125	
	DR	Simm, L.G. et al. (1993) J Virol 67(7), 3969-77	
	DS	Thompson, J.D. et al (1994) Nucl. Acids Res. 22, 4673-4680	
	DT	Truant, R., and B.R. Cullen (1999) Mol Cell Biol 19, 1210-1217	
	DU	Wecker, K., and B.P. Roques (1999) Eur J Biochem 266, 359-369	
	DV	Yuan, X. et al. (1990) AIDS Res and Human Retroviruses 6(11), 1256-71	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.